Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	50.7	0	0	0	0	0	0	0
Cost of Revenue	3.09	0	0	0	0	0	0	0
Gross Profit	47.61	0	0	0	0	0	0	0
Selling, General & Admin	98.4	77.74	40.39	15.06	6.47	4.16	1.56	0.4
Research & Development	46.43	42.46	27.88	17.94	15.62	7.76	3.21	0.74
Other Operating Expenses	12.5	25	0	0	0	0	0	0
Operating Expenses	157.33	145.2	68.28	33	22.08	11.92	4.77	1.14
Operating Income	-109.73	-145.2	-68.28	-33	-22.08	-11.92	-4.77	-1.14
Interest Expense / Income	0	0	1.49	0	0	0	3.15	0.01
Other Expense / Income	-122.62	-5.22	-0.2	-0.83	-2.99	-1.03	-	-
Pretax Income	12.9	-139.98	-69.57	-32.17	-19.09	-10.89	-7.92	-1.15
Income Tax	1.97	0	0	0	0	0	0	0
Net Income	10.93	-139.98	-69.57	-32.17	-19.09	-10.89	-7.92	-1.15
Shares Outstanding (Basic)	27	25	22	19	16	11	5	1
Shares Outstanding (Diluted)	28	25	22	19	16	11	5	1
Shares Change	8.87%	14.84%	18.15%	18.15%	41.93%	108.99%	510.89%	-
EPS (Basic)	0.40	-5.49	-3.13	-1.71	-1.20	-0.97	-1.48	-1.31
EPS (Diluted)	0.39	-5.49	-3.13	-1.71	-1.20	-0.97	-1.48	-1.31
Free Cash Flow	-0.6	-153.55	-116.27	-40.93	-25.09	-11.68	-4.1	-1.33
Free Cash Flow Per Share	-0.02	-6.02	-5.24	-2.18	-1.58	-1.04	-0.77	-1.51
Gross Margin	93.90%	-	-	-	-	-	-	-
Operating Margin	-216.43%	-	-	-	-	-	-	-
Profit Margin	21.56%	-	-	-	-	-	-	-
Free Cash Flow Margin	-1.19%	-	-	-	-	-	-	-
Effective Tax Rate	15.24%	-	-	-	-	-	-	-
EBITDA	17.9	-137.33	-66.23	-30.32	-18	-10.75	-4.75	-1.14
EBITDA Margin	35.31%	-	-	-	-	-	-	-
Depreciation & Amortization	5.01	2.64	1.85	1.85	1.09	0.14	0.02	0
EBIT	12.9	-139.98	-68.08	-32.17	-19.09	-10.89	-4.77	-1.14
EBIT Margin	25.44%	-	-	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).